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Although Candida albicans is the most common human yeast pathogen, other Candida species such as C.
krusei are now recognized as emerging agents, especially in patients with human immunodeficiency virus (HIV)
disease. C. krusei is inherently resistant to the widely used triazole antifungal fluconazole and poses therapeutic
problems, especially in systemic candidiasis. In a surveillance study of leprosy patients (with arrested or
burnt-out disease) in a leprosarium in northern Thailand, we found a rate of oral carriage of C. krusei (36%)
significantly (P < 0.05) higher than that for a healthy control group (10%). Among the Candida-positive
patients, 16 of 35 (46%) carried C. krusei, while C. albicans was the second most common isolate (12 of 35
patients; 34%). The corresponding figures for the control group were 2 of 13 (15%) and 6 of 13 (46%),
respectively. Studies of the antifungal resistance of the C. krusei isolates from patients indicated that all except
one of the isolates were resistant to fluconazole, two isolates were resistant to ketoconazole, and all isolates
were sensitive to amphotericin B. Evaluation of their genetic profiles by randomly amplified polymorphic DNA
analysis with three different primers and subsequent analysis of the gel profiles by computerized cluster-
derived dendrograms revealed that the C. krusei isolates from patients belonged to 10 disparate clusters,
despite the origin from a single locale. These nascent findings indicate an alarmingly high prevalence of a
Candida species resistant to a widely used antifungal in a part of the world where HIV disease is endemic.
Leprosy is caused by Mycobacterium leprae and is a disease
of global prevalence (18). Reports from 91 countries indicate
that at the beginning of the new millennium 641,091 patients
with leprosy were registered for treatment, although the real
numbers may be much higher (27). There are regional varia-
tions in the prevalence of leprosy; its global prevalence rate
is estimated to be 1.25 per 10,000 population. The Thailand
Leprosy Registry contained 2,291 cases at the beginning of
2000, yielding a prevalence rate of 0.4 per 10,000 habitants
(27). Since the introduction of cocktail, multidrug therapy
(MDT), consisting of a combination of rifampin, clofazimine,
and dapsone, the prognosis of leprosy has improved dramati-
cally, with more than 10 million patients cured by the end of
1999.
Leprosy may manifest as indeterminate, tuberculoid, bor-
derline, and lepromatous variants (9). While all of these may
be associated with orofacial pathology (14), most oral lesions
are recorded in lepromatous leprosy patients (11). Facial le-
sions include granulomatous skin lesions and other cutaneous
adnexa, particularly of the facial and trigeminal nerves (15).
Leproma formation, especially in the soft palate, may lead to
the extensive loss of soft tissue and palatal perforations (12).
In addition, the gingiva and periodontium as well as the
facial skeleton including the alveolar process may be involved
(1, 13).
Arrested or chronically treated (colloquially termed burnt-
out) leprosy has been defined as a case in which mycobacteria
are no longer produced either as a consequence of a lifelong
course of leprosy or due to MDT. Patients with arrested lep-
rosy are characterized by severe mutilations of limbs and oro-
facial alterations. Many have a saddle nose and severe ocular
pathology including blindness (14). Due to these severe dis-
abling conditions, many of these relatively elderly patients are
hospitalized or live permanently in leprosy rehabilitation cen-
ters, especially in Thailand, where they form small communi-
ties of various sizes. Patients live close together, sharing bed-
rooms and taking their meals in a community setting.
Extensive perusal of the electronic and archival data sources
in the English-language literature indicated that there is vir-
tually no information on the oral mycotic flora of leprosy
patients. Hence, we embarked on the cross-sectional study
described here to investigate an institutionalized resident pop-
ulation of arrested leprosy patients in Thailand. The study
cohort from the McKean Rehabilitation Center, Chiangmai,
Thailand, was particularly interesting as it comprised an el-
derly population that had been confined to the center for a
prolonged period and that had undergone extended periods
of medication. First, a pilot, cross-sectional study was un-
dertaken to evaluate the prevalence of Candida species in
this cohort. As this study indicated that Candida krusei was
present in an unusually large numbers of people in the co-
hort, we proceeded to analyze in detail the genotypes and
the antifungal sensitivities of the isolates in order to further
characterize this uncommon oral yeast now considered an
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emerging pathogen, especially among compromised patient
groups (17, 22).
MATERIALS AND METHODS
Patients. The patients selected were all long-term residents at the McKean
Rehabilitation Center, which especially caters to leprosy patients. The inclusion
criteria for the patients were as follows: (i) the patients had to have arrested
leprosy of long duration and a negative bacillary index, (ii) the patients could not
have received any antileprosy therapy (MDT), and (iii) the patients had to be
handicapped (e.g., mutilation of limbs) with or without the orofacial changes of
the late stage of leprosy. None of the patients elicited a history of recent oral
candidiasis and as such had not been exposed to antifungals. It is also noteworthy
that neither the patients nor the controls included in the study were infected with
human immunodeficiency virus (HIV), nor, to our knowledge, had they been in
close contact with HIV-infected individuals. Furthermore, as the patients had
arrested leprosy, they were not receiving any drugs (e.g., dapsone or thalido-
mide) that may have led to functional disturbances in systemic immunity.
All patients were examined by one examiner (P.A.R.) under an artificial light
in a dental chair at the dental unit of the center. The following parameters were
recorded: age, sex, type and duration of leprosy, period of hospitalization, type
of previous antileprosy therapy, and period since a negative bacillary smear was
recorded.
The oral cavities were examined for the presence of dentures and oral mucosal
changes, in particular, oral candidiasis. If dentures were present, they were
removed prior to sampling. The same collector obtained control samples from 20
adults residing in the same locale using sampling techniques identical to those
used for the leprosy patients.
Sampling procedures and stock maintenance. For evaluation of candidal car-
riage, the tongue and palate of each patient were sampled by rigorously swabbing
their surfaces with a sterile Fungi-Quick swab (Hain Diangostika, Berlin, Ger-
many). Afterwards the swab was reinserted into the alginate transport medium
within the tube and kept at room temperature for immediate transport to the
Oral Biology Laboratory at the Prince Philip Dental Hospital, Hong Kong. The
swabs were then cultured aerobically on Sabouraud dextrose agar at 37°C for 7
days. The cultures were inspected on a daily basis for yeast growth, and plates of
pure isolates were obtained, if any were present. The pure cultures were stored
in glycerol at 70°C until species identification and genetic fingerprinting.
Identification of Candida species. The Candida organisms were identified by
the germ tube test, growth at 45°C, chlamydospore production, and API 20C
AUX (Bio-Merieux, Marcy l’Etoile, France) assimilation tests; and the pheno-
type was further defined by using CHROMagar Candida plates (CHROMagar,
Paris, France) (20). Their identities were reconfirmed with the new improved
APILAB Plus system (Bio-Merieux) to exclude Candida dubliniensis. Carriage
was defined as the presence of yeasts on inoculated plates; attempts were not
made to quantify the oral yeast load per individual.
Antifungal sensitivity testing. Commercially available antifungal susceptibility
gradient strips (E-test; AB BIODISK, Solna, Sweden) were used for direct
quantification of MICs. The antifungal agents used were amphotericin B, keto-
conazole, and fluconazole, and the range of concentrations of the antibiotics to
which susceptibilities were tested was 0.002 to 256 g/ml, respectively.
The procedures followed for antifungal susceptibility testing by the E-test were
those recommended by the manufacturer (E-test technical guide number 4,
Antifungal susceptibility of yeasts, AB BIODISK). The medium used to test the
sensitivities was RPMI 1640 (American Bioorganics, Buffalo, N.Y.) with 2%
glucose, as prescribed by the NCCLS; the depth of agar in each plate was 4.0 to
0.5 mm (8).
Well-isolated yeast colonies from a 24-h growth on Sabouraud agar were
inoculated in 0.85% NaCl and adjusted spectrophotometrically at 530 nm to
match the turbidity of a 0.5 McFarland standard. These suspensions were inoc-
ulated onto the agar with sterile cotton wool swabs by swabbing the entire surface
evenly in three directions. After the surface was allowed to dry for 15 min, the
E-test strips were applied. The plates were then incubated at 35°C for up to 48 h
in a moist incubator until growth was seen. In the case of the azoles, the plates
were first read at 24 h, and the reading was confirmed after 48 h. The lowest drug
concentration on the E-test strip inhibiting 100% of the growth was defined as
the MIC, according to the instructions provided by the manufacturer.
DNA isolation for randomly amplified polymorphic DNA (RAPD) analysis.
For the isolation of DNA, the yeasts were grown on Sabouraud dextrose agar
plates (Oxoid, Basingstoke, United Kingdom) for 24 h at 37°C. The yeast cells
were scraped from the plate, washed in 1 M sorbitol, and incubated at 37°C for
1 h in 1 ml of SE buffer (1.2 M sorbitol, 0.1 M EDTA [pH 7.5]) containing 1 l
of -mercaptoethanol (Sigma, St. Louis, Mo.) and 0.3 mg of yeast lyticase
(Sigma). The resulting spheroplasts were harvested by centrifugation at 10,000
rpm for 1 min on a Beckman (Fullerton, Calif.) centrifuge (model G515R),
washed once in SE buffer, and resuspended in 0.4 ml of 0.15 M NaCl–0.1 M
EDTA (pH 7.5). They were lysed by the addition of proteinase K (final concen-
tration, 400 g/ml; Gibco BRL, Life Technologies, Inc., Gaithersburg, Md.) and
sodium dodecyl sulfate (final concentration, 1% [wt/vol]) along with RNase A
(final concentration, 400 g/ml) (Sigma) at 55°C for 1 h. After centrifugation, the
supernatants were extracted twice with phenol-chloroform-isoamyl alcohol and
once with chloroform, and then the DNA was precipitated with 2-propanol.
Once the DNA was extracted and purified, the DNA was dissolved in 50 l of TE
buffer (10 mM Tris, 0.1 mM EDTA [pH 8.0]) and stored at 4°C until further
analysis (2).
RAPD analysis. RAPD analysis of C. krusei with primers OBU1 (5CAC ATG
CTT3), OBU2 (5CAC ATG CCT3), and RSD11 (5GCA TAT CAA TAA
GCG GAG GAA AAG3) was carried out in a 50-l final volume containing 1
M primer, 2 mM MgCl2, 1 PCR buffer (200 mM Tris-HCl [pH 8.4], 500 mM
KCl), 200 M deoxynucleoside triphosphates, 1.5 U of Taq DNA polymerase
(Gibco BRL, Life Technologies, Inc.), and 200 ng of yeast DNA as the template
(3). These primers were chosen after extensive pilot studies with a battery of six
primers (unpublished data) due to their relatively high discriminatory powers, as
described previously (2, 2a, 3). The first 5 cycles included 30 s of denaturation at
94°C, 2 min of annealing at 27°C (for primers OBU1 and OBU2) or 52°C (for
primer RSD11), and 2 min of primer extension, followed by 45 cycles of 30 s of
denaturation at 94°C, 2 min of annealing at 32°C (for primers OBU1 and OBU2)
or 57°C (for primer RSD11), and 2 min of primer extension at 72°C. The reaction
was held at 72°C for 10 min. Control tubes with no template DNA were included
in each run, and the reproducibility of the reaction was checked. The amplifica-
tion products were separated on 1.2% agarose gels in 0.5 TBE (Tris-borate-
EDTA) buffer, stained with ethidium bromide, and visualized on a UV transil-
luminator.
Analysis of DNA fingerprints. The RAPD fingerprint patterns of each isolate
were analyzed according to their band positions. The data for two banding
patterns (lanes A and B) can be classified by the binary values 0 and 1, where 0
indicates no band at a position and 1 indicates a band at that position. The





where a is the number of bands common for both lanes A and B (coded 1,1), b
is the number of bands in lane A with no counterpart in lane B (coded 1,0), and
c is the number of bands in lane B with no counterpart in lane A (coded 0,1). An
SAB value of 0.80 was arbitrarily used as the threshold for clustering of similar
strains, since it is roughly halfway between the average value for dissimilarity and
identity.
A computerized dendrogram method (the Dendron software program) based
on SAB was used to cluster the isolates (23) on the basis of the pairwise similarity
coefficient matrix. In the Dendron program, the two strains with the highest
similarity coefficients are grouped, with the branch point corresponding to the
SAB. The program then searches for a strain(s) with the next highest SAB and
groups them, with the branch point corresponding to the SAB. The process
continues sequentially until all strains are included and then derives a tree of
similarity. This method was used to generate the dendrogram profiles for all 16
isolates with each of the three primers used in the RAPD analysis.
RESULTS
Demographic data for patients and controls. A total of 44
patients (22 men, 22 women) with a mean age of 72.8 years
(age range, 60 to 89 years) were examined. On average, the
patients had spent 25.7 years as inpatients (range, 60 months to
60 years), with a mean period of leprosy of 42.9 years (median,
48 years; range, 7 to 70 years).
The majority of patients (n  28; 63.6%) had lepromatous
leprosy; 2 (4.5%) had a history of tuberculoid leprosy, and 14
(31.8%) had borderline (tuberculoid) leprosy. The average
period since these patients had had a negative bacillary smear
was 11.5 years (median, 17.5 years). The patients had been










microbiologically negative for mycobacteria for between 2 and
45 years.
Dentures were present in 8 of 44 patients, and 1 patient had
clinical manifestations of denture stomatitis. Other oral muco-
sal findings were median rhomboid glossitis (n  2 patients),
leukoedema (n  12), geographic tongue (n  1), oral lichen
planus (n  1), oral leukoplakia (n  1), lichenoid reaction
(n  1), fibroma (n  1), and betel chewer’s mucosa (n  2).
Seven patients had a complete or partial loss of the uvula due
to leproma at a previous stage of the disease, and three others
had incompetent lips due to facial disfigurement.
The control group of nonleprosy patients, also from the
McKean Rehabilitation Center, were long-term residents be-
cause of neurological diseases and debilitation. They lived in
separate wards for men and women situated some distance
away from the leprosy wards. None of them had acute oral
infections or were receiving antifungal agents; none of the
controls wore dentures.
Oral yeast prevalence rates in leprosy patients. The rates of
oral yeast carriage were relatively high in both the leprosy
patients and the controls. Among the individuals in the patient
group, 35 of 44 (80%) carried yeasts, whereas 13 of 20 (65%)
of the control adults sampled carried yeasts (P  0.05 by
Fisher’s exact test).
When the species of the organisms from the leprosy patients
were identified, the majority of the yeasts were found to be C.
krusei (16 of 35; 46%), while C. albicans was the second most
common yeast (12 of 35; 34%), with the remainder belonging
to the species Candida tropicalis, Candida guilliermondii, Can-
dida rugosa, Candida famata, Candida parapsilosis, and Pichia
ohmeri (Table 1). Two of the 13 Candida-positive patients in
the control group carried C. krusei, while the others harbored
C. albicans, C. tropicalis, C. parapsilosis, Saccharomyces cerevi-
siae, and Hansenula polymorpha. Considering the overall rate
of oral candidal carriage in the two populations studied, the
patients had a significantly higher oral prevalence of C. krusei
(16 of 44; 36%) than the healthy controls (2 of 20; 10%) (P 	
0.05).
Phenotypes of C. krusei. According to the API 20C AUX
assimilation profiles, the 16 C. krusei isolates from the control
group could be categorized into four different phenotypes.
Thus, a total of 12 isolates belonged to classic phenotype
2000000, isolates L21 and L38 belonged to phenotype 2000100,
isolate L24 belonged to phenotype 6000000, and isolate L38
belonged to phenotype 6000100.
Antifungal sensitivities of C. krusei isolates. All except one
of the C. krusei isolates (isolate L24, for which the fluconazole
MIC was 192 g/ml) were resistant to fluconazole (MIC, 64
g/ml), according to the breakpoint definitions proposed by
Rex et al. (16) (Table 2).
All C. krusei isolates were sensitive to amphotericin B, with
an MIC range of 0.032 to 2.00 g/ml (normal range, 0.050 to
6.25 g/ml) (8).
Due to the lack of consensus definitions of breakpoints for
ketoconazole MICs, arbitrary values were established, accord-
ing to those suggested in previous publications: susceptible for
isolates for which MICs were 	0.125 g/ml, susceptible dose
dependent for isolates for which MICs were between 0.25 and
0.5 g/ml, and resistant for isolates for which MICs were 1
g/ml. According to these criteria, 12% of our isolates were
resistant to ketoconazole and another 12% were deemed sus-
ceptible dose dependent, while the remainder were susceptible
(16).
Interestingly, the two isolates which exhibited resistance to
ketoconazole (isolates L21 and L38) were the most resistant to
amphotericin B.
RAPD genotypes and dendrogram profiles of C. krusei. We
wished to determine whether the 16 strains of C. krusei isolated
from leprosy patients belong to either a distinct genetic group
TABLE 1. Identities of Candida species isolated from leprosy






L2 C. krusei 2000000
L3 C. albicans 1 2776174
L4 C. albicans 1 2576174
L6 P. ohmeri 6156176
L7 C. krusei 2000000
L8 C. krusei 2000000
L10 C. krusei 2000000
L11 C. krusei 2000000
L12 C. rugosa 2042100
L13 C. krusei 2000000
L14 C. krusei 2000000
L15 C. albicans 1 2576174
L16 C. guilliermondii 6776373
L17 C. albicans 1 2576174
L18 C. parapsilosis 6752135
L19 C. tropicalis 2557375
L21 C. krusei 2000100
L23 C. albicans 1 2576174
L24 C. krusei 6000000
L25 C. famata 6576371
L27 C. krusei 2000000
L28 C. krusei 2000000
L29 C. krusei 2000000
L31 C. albicans 1 2576174
L33 C. albicans 1 6176174
L34 C. albicans 1 2566174
L35 C. albicans 1 2576174
L37 C. albicans 1 2576174
L38 C. krusei 6000100
L39 C. krusei 2000100
L40 C. krusei 2000000
L41 C. krusei 2000000
L42 C. albicans 1 2576174
L43 C. tropicalis 2576175
L44 C. albicans 1 2576174
Control subjects
C2 C. albicans 1 2576174
C4 S. cerevisiae 1 2044030
C6 C. parapsilosis 6756171
C11 C. albicans 1 2576174
C12 H. polymorpha 6036071
C13 C. albicans 1 2576174
C14 C. krusei 2000100
C15 C. albicans 1 2576174
C16 C. albicans 1 2576174
C17 C. parapsilosis 6756171
C18 C. krusei 2000100
C19 C. tropicalis 2556171
C20 C. tropicalis 2556171
a No yeasts were isolated from patients L1, L5, L9, L20, L22, L26, L30, L32,
and L36 and control subjects C1, C3, C5, and C7 to C10.










or disparate genetic groups. For this purpose the C. krusei
isolates were genotyped by the RAPD technique with three
different primers, primers OBU1, OBU2, and RSD11. The
RAPD profiles thus obtained are shown in Fig. 1. By examin-
ing the band profiles one can determine, even without the aid
of computer assistance with the Dendron program, that the
patterns of commensal C. krusei strains differed from each
other by the positions of one or more bands. However, some
patterns were similar. For example, with primers OBU1 and
RSD11, the patterns of isolates L27 and L28 differed by only
one intense band. Again, with primer OBU2, the patterns of
isolates L40, L29, and L41 were almost identical.
The relationships between strains and patterns are best vi-
sualized in dendrograms based on computed SABs (Fig. 2).
Hence, to determine whether the 16 C. krusei strains from the
patients represent a distinct genetic group, we further analyzed
the dendrogram profiles of the gels obtained with the three
different primers. An SAB value of 0.80 was arbitrarily used as
the threshold for clustering of similar strains. The three differ-
ent primers (primers OBU1, OBU2, and RSD11) categorized
the 16 isolates into 14, 12, and 10 clusters, respectively.
The dendrograms of these strains showed various relation-
ships, with SAB values ranging from 0.99 for the relationship
between isolates L27 and L28 obtained with primer OBU1 to
0.55 for the relationship between isolate L39 and the group
containing all the other strains obtained with primer OBU2. A
genetically identical cluster with an SAB of 1 was noted with
isolates L27 and L28 with OBU1 and isolates L40, L29, and
L41 with OBU2. The dendrograms also revealed the various
profiles that can be generated when different primers are used
to characterize the genotypic profiles. In summary, it was clear
from the dendrograms that there was considerable genetic
diversity and the existence of genetic shuffling among the iso-
lates within this particular locale, irrespective of the primer
used.
DISCUSSION
There are no reports in the literature on the oral carriage of
Candida species in cohorts of patients with either active or
arrested leprosy. Hence, we embarked on this study to obtain
baseline data on oral yeast carriage and for this purpose sought
a group of reclusive individuals with minimal contact with the
outside world. The residents of the McKean Rehabilitation
Center were chosen, as the center is a long-established rural
unit with a live-in population, with some of the patients having
lived at the center for up to 70 years.
For practical reasons and because of the difficulty of airlift-
ing (i.e., transport by air to another laboratory for analysis) of
the samples, oral yeast carriage was evaluated by a swabbing
technique, which is considered less reliable than the oral rinse
technique (21). Nonetheless, the former technique is widely
practiced in field studies and is well established (20). We were
therefore surprised to note the very high oral yeast carriage
rate (80%) in the patient cohort, despite the use of the less
reliable technique. The oral yeast carriage rate in healthy pop-
ulations ranges from 2.0 to 71% (20), and it may increase up to
95% in patients with particular disease states, such as in HIV
infection (19).
Perhaps the most intriguing and interesting finding in our
study was the significantly higher prevalence of C. krusei in the
patient population than in the control population (36 versus
10%). C. albicans isolates, the most predominant species in
humans, were present but were the second most common
yeasts isolated. On comprehensive perusal of 44 publications in
the literature for which statistics on rates of human carriage of
C. krusei were available, the highest carriage rates were found
to be 6.1% for the oral cavity, 10.3% for the gastrointestinal
tract, and 12.5% for the vagina either in health or in disease
(22). Although we are unable to forward a hypothesis for this
exceptionally high prevalence of C. krusei in our cohort, it is
tempting to speculate that the institutionalization and the
shared dietary regimens possibly originating from a common
outlet may have played a role in this phenomenon. Nonethe-
less, the genomic data indicated clearly that the yeasts were not
derived from a single source (see below).
While diet has been proven to be one of the main etiological
factors in dental caries, its effect on general oral health and
especially the oral microflora is less clear. The flow rate and
buffering capacity of whole saliva, but not the numbers of
mutans group streptococci and lactobacilli, have been shown to
increase following the transition from a mixed diet to a lacto-
vegetarian diet in one Swedish study (5), whereas the stimu-
lated salivary flow rate in lactovegetarians was lower than that
in nonvegetarians in another Scandinavian study (7). A dimin-
ished salivary flow rate, generally seen in older individuals,
could contribute to the relatively high rate of oral carriage of
Candida in our study. Yet, why this would predispose the
individuals to the growth of C. krusei in preference to other
species remains to be examined. Compared to other medically
important Candida species, such as C. albicans, C. krusei has
been isolated from a large variety of natural habitats. These
include the atmosphere, fruits, sewage, silage, soil, wine, and
TABLE 2. MICs of amphotericin B, fluconazole, and ketoconazole




Amphotericin Ba Fluconazoleb Ketoconazolec
L2 0.064 256 0.064
L7 0.094 256 0.094
L8 0.125 256 0.047
L10 0.125 256 0.047
L11 0.094 256 0.064
L13 0.047 256 0.064
L14 0.094 256 0.012
L21 1.500 256 3.000
L24 0.380 192 0.250
L27 0.032 256 0.047
L28 0.094 256 0.047
L29 0.094 256 0.047
L38 2.000 256 6.000
L39 0.064 256 0.380
L40 0.094 256 0.032
L41 0.250 256 0.064
a All isolates were sensitive to amphotericin B.
b All isolates except isolate L24 were resistant to fluconazole.
c Ketoconazole resistance was seen for isolates L21 and L38, and dose-depen-
dent ketoconazole susceptibility was seen for isolates L8, L10, L24, and L40 (see
text for details).










FIG. 1. RAPD fingerprinting patterns of 16 C. krusei isolates (derived from the oral cavities of arrested leprosy patients) with primers OBU1,
OBU2, and RSD11 after separation by electrophoresis on a 1.2% agarose gel. Lanes M, molecular marker (bacteriophage 
 DNA cleaved with
HindIII).










beer (4). It is also found in chickens and seagulls (10). In recent
years C. krusei has been recognized as an important agent of
nosocomial candidiasis due to its increasing incidence and in-
herent resistance to azoles, especially fluconazole (22). Hence,
it is considered a facultative saprophyte which may cause op-
portunistic infections only when host defenses are impaired.
The most widely used antifungal agents are the polyenes and
the azoles, which include the imidazoles and the newer tria-
zoles. As stated previously (8), almost all C. krusei strains are
inherently resistant to fluconazole, and accordingly, all such
isolates from leprosy patients demonstrated this resistance pat-
tern. All 16 isolates were also uniformly sensitive to ampho-
tericin B (MIC range, 0.032 to 2.000 g/ml; normal MIC range,
0.05 to 6.25 g/ml). However, 2 of the 16 isolates (isolates
L21 and L38) were resistant to ketoconazole, according to
recent NCCLS criteria (16). As far as we are aware, the cohort
has not recently received azole therapy, and the ketoconazole
resistance exhibited by 2 of 16 C. krusei isolates therefore
appears to be intrinsic in nature.
When the phenotypes of the C. krusei isolates were com-
pared, they could be classified into four distinct biotypes ac-
cording to the API 20C AUX system. All isolates were positive
for glucose, and this was the only positive reaction seen with 12
isolates (75%; with a profile of 2000000). Of the remainder of
the isolates, two isolates (isolates L21 and L39; 12.5%) were
positive for glucose and N-acetyl-glucosamine (with a profile of
2000100); one isolate (isolate L38) was positive for glucose,
glycerol, and N-acetyl-glucosamine (with a profile of 6000100);
and another isolate (isolate L24) was positive for glucose and
glycerol (with a profile of 6000000).
The biotyping system described above is relatively nondis-
criminatory, as C. krusei species are notorious for their weak
reactivities with the standard chemicals used in commercial
systems such as the API 20C AUX system that we used. Fur-
thermore, the method is inherently flawed, as it compares
phenotypes, thus running the risk of separating strains which
are genetically similar yet phenotypically dissimilar or vice
versa (26). Recently, several methods for the genotyping of C.
krusei and the generation of strain-specific profiles have been
described (2a). These include (i) pulsed-field gel electrophore-
sis, a technique which improves chromosomal separation with
excellent resolving power, (ii) the restriction fragment length
polymorphism analysis method, in which the yeast DNA is
cleaved by various restriction enzymes to generate strain-spe-
cific profiles, and (iii) the RAPD analysis method, in which
specific short oligonucleotide fragments can be arbitrarily
primed at multiple positions of the yeast genome for PCR
assays. We used the last technique, as it has proved to be a
useful tool for C. krusei strain delineation in our hands (3),
especially in combination with the recently developed comput-
er-assisted system with Dendron software for gel analysis (24).
Furthermore, a number of workers have found that the RAPD
technique is reliable and versatile for clinical epidemiological
analysis of Candida populations, as little DNA sample is re-
quired and also because of the simplicity of the technique (for
recent reviews, see references 2a and 26).
As in previous work (6), we used a total of three primers in
order to generate various brand profiles for the 16 isolates
(Fig. 1). When these results were analyzed by use of the Den-
dron program, which clusters organisms according to their
FIG. 2. Dendrograms generated from SABs computed for pairwise
comparisons of 16 isolates of C. krusei and fingerprinted with three
different primers (primers OBU1, OBU2, and RSD11). SABs were
calculated by using band positions alone (see Materials and Methods).










SABs, the data obtained with primers OBU 1, OBU2, and
RSD11 generated 14, 12, and 10 clusters, respectively, with an
SAB of 0.8 (Fig. 2). Accordingly, primer OBU1 was the most
discriminant, while primer RSD11 was the least. These results
suggest that genetic shuffling does occur among the oral C.
krusei isolates from the patients studied, despite the restricted,
ring-fenced, tight geographic niche in which they live and de-
spite the lack of extraneous contaminant sources by virtue of
the stigmatized disease state of the patients.
On comparison of the phenotypes and the genotypes of the
isolates, it was evident that strains L24 and L38, which had
unique phenotypes, were also genetically similar, as they
formed a closely related cluster in assays with both primer
OBU2 and primer RSD11. Subspecies variations in C. krusei
have previously been documented (18, 25). The current data
add credence to these observations. Further research is war-
ranted to reclassify these variants.
In conclusion, our data provide a tantalizing glimpse of the
oral mycotic flora in an as yet undescribed patient population.
Most importantly, the findings presented here reveal the high
prevalence of C. krusei in the cohort studied and the intrigu-
ingly divergent genomic profiles of the strains isolated. In bi-
ological terms, the prolific diversity of such a relatively innoc-
uous opportunistic pathogen is surprising and warrants further
study.
In view of the predominance of a triazole-resistant C. krusei
strain in the population studied and the high prevalence and
incidence of HIV infection in northern Thailand, which in turn
predisposes individuals to candidiasis, similar prevalence stud-
ies should be pursued with other regional population groups. If
such data indicate a predominance of this yeast in the general
populace, this may have implications for the protocols guiding
the management of HIV-related candidiasis, in which flucon-
azole is the drug of choice.
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